Optimal pharmacotherapy for transplant ineligible multiple myeloma
CADTH
Record ID 32018002252
English
Original Title:
Optimal pharmacotherapy for transplant-ineligible multiple myeloma
Authors' objectives:
Multiple myeloma (MM) is a hematological cancer that mainly affects individuals older than 65 years of age. Though MM remains incurable, several life-prolonging pharmacotherapies for the treatment of newly diagnosed, relapsed, or refractory MM were reviewed by CADTH and are available or being considered for public reimbursement in Canada. However, at this time, the optimal sequence of therapies is unclear. CADTH is preparing a Therapeutic Review considering multiple MM drugs and treatment steps in order to help decision-makers develop appropriate pharmaceutical funding policies.
Details
Project Status:
Ongoing
URL for protocol:
https://www.cadth.ca/sites/default/files/ou-tr/TR0014-multiple-myeloma-protocol-final.pdf
Anticipated Publish Date:
2022
URL for additional information:
https://cadth.ca/optimal-pharmacotherapy-transplant-ineligible-multiple-myeloma
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
Canada
MeSH Terms
- Multiple Myeloma
- Drug Therapy
Keywords
- Multiple myeloma
- Drug therapy
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
<p>Canadian Agency for Drugs and Technologies in Health (CADTH)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.